As filed with the Securities and Exchange Commission on November 30, 2023
Registration No. 333-249774
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
The
Securities Act of 1933
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO.
333-249774
SQZ
BIOTECHNOLOGIES COMPANY
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
|
46-2431115 |
(State or other jurisdiction of
incorporation or organization) |
|
(IRS Employer
Identification No.) |
PO Box 5515
Wayland, MA 01778
(Address of principal executive offices) (Zip code)
SQZ Biotechnologies Company 2014 Stock Incentive Plan, as amended
SQZ Biotechnologies Company 2020 Incentive Award Plan
SQZ Biotechnologies Company 2020 Employee Stock Purchase Plan
(Full title of the plans)
Howard Bernstein, M.D., Ph.D.
Interim Chief Executive Officer
SQZ Biotechnologies Company
PO Box 5515
Wayland, MA
01778
(Name and address of agent for service)
(617) 758-8672
(Telephone number, including area code, of agent for service)
Copy to:
Peter
N. Handrinos, Esq.
Wesley C. Holmes, Esq.
Latham & Watkins LLP
200 Clarendon Street, 27th Floor
Boston, MA 02116
(617) 948-6000
Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated
filer, accelerated filer and smaller reporting company, emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐